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High DNA-methyltransferase 3B expression predicts poor
outcome in acute myeloid leukemia, especially among patients
with co-occurring NPM1 and FLT3 mutations
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DNA methyltransferases (DNMTs) are epigenetic regulators
targeted to the treatment of hematological malignancies.1–4
Mutations in the DNA methyltransferase DNMT3A and high
expression of its paralogue DNMT3B have been associated with
inferior outcome in acute myeloid leukemia (AML) and other
hematological malignancies.5–8 Using a publicly available gene
expression data set,9 we studied whether DNMT3B expression
correlates with outcome in genetically well-deﬁned AML
subgroups. We ﬁrst validated the expression data from the
microarray by quantitative PCR, using 39 patient samples
(Supplementary Figure S1A). DNMT3B micro-array analyses
showed that the expression was not normally distributed among
AML patients; in the quartile with highest expression, a larger
variation in expression was observed compared to the three
quartiles with relatively lower expression (Supplementary Figure
S1B). The median DNMT3B expression in AML samples was
signiﬁcantly lower compared with that observed in normal bone
marrow (NBM)-derived CD34+ cells (Po0.0001), while it was
higher compared to NBM cells, but the latter difference was not
statistically signiﬁcant (Supplementary Figure S1B). Subsequently,
we investigated the correlation between DNMT3B expression and
overall survival (OS) and event-free survival (EFS). In univariate Cox
regression analyses, continuous DNMT3B expression was signiﬁ-
cantly associated with poor survival (Po0.001 for both OS and
EFS, data not shown). To visualize the prognostic impact, we
performed Kaplan–Meier analyses on the four quartiles based on
expression levels. The quartile including the patients with the
highest DNMT3B expression, exhibiting the largest variation in
expression, showed a signiﬁcantly reduced OS and EFS compared
to the other quartiles (Supplementary Fig. S2). As the survival
between the lower three quartiles did not differ signiﬁcantly, we
grouped these patients together as having lower DNMT3B
expression, whereas the remaining patients were ranked as
having higher DNMT3B expression. Using these criteria, the
5-year OS and EFS were 17.2%± 3.3% and 13.6%±3.0% for
patients with higher DNMT3B expression compared to
43.8%±2.5% and 34.4%±2.4% for patients with lower DNMT3B
levels (Po0.001, Figure 1a). We next performed a multivariate Cox
regression analysis including known prognostic factors (including
age460 years; white blood cell counts4100×109/l; transplantation
status; karyotypes t(8;21), t(15;17) and inv(16); nucleophosmin 1
(NPM1), FLT3-ITD, DNMT3A and double CEBPA mutations, and
ecotropic viral integration site 1 (EVI1) overexpression), which
revealed that higher DNMT3B expression carried an independent
prognostic risk for both OS and EFS (hazard ratio (HR): 1.768, 95%
conﬁdence interval (CI): 1.384–2.260; Po0.001 and HR: 1.706, 95%
CI: 1.342–2.168; Po0.001, respectively, Table 1), in line with a
recently published study.7 In fact, higher DNMT3B expression
showed a higher hazard ratio for OS than that of well-known
adverse prognostic factors such as internal tandem duplications of
the fms-related tyrosine kinase 3 (FLT3-ITD, HR: 1.675, 95%
CI: 1.287–2.179; Po0.001) and overexpression of the EVI1 gene
(HR: 1.430, 95% CI: 0.999–2.047; P= 0.051).
We then studied the association of higher DNMT3B expression
with speciﬁc AML subcategories. Higher DNMT3B expression was
under-represented in FAB-M4 and mutually exclusive with the
favorable karyotypes t(8;21) and inv(16), as shown in
Supplementary Table S1. In contrast, higher DNMT3B expression
was over-represented in the FAB-M1 subcategory (Supplementary
Table S1), and predicted poor OS and a trend toward poor EFS in
this group (data not shown). A signiﬁcant association between
higher DNMT3B expression and EVI1 overexpression and IDH2
mutations was also observed (Supplementary Table S1), but not
with IDH1 mutations. DNMT3B expression did not predict clinical
outcome in these subgroups (data not shown). We also observed
that higher DNMT3B expression was associated with a normal
karyotype (NK, P= 0.017), and strongly associated with mutations
in NPM1 (NPM1+, Po0.001) and FLT3-ITD (FLT3-ITD+, Po0.001,
Supplementary Table S1). Patients with NK can be classiﬁed based
on NPM1 and FLT3-ITD mutational status. NPM1 mutations,
particularly in the absence of FLT3-ITD, display a favorable disease
outcome, whereas the presence of a FLT3-ITD mutation is
generally considered as an adverse prognostic factor.10 Remark-
ably, among patients with NK, higher DNMT3B expression did not
signiﬁcantly associate with NPM1−/FLT3-ITD− status and was
under-represented in the NPM1+/FLT3-ITD− and NPM1−/FLT3-ITD+
groups, but was signiﬁcantly over-represented in the NPM1+/FLT3-
ITD+ group (Supplementary Table S2). Within the latter group,
patients with higher DNMT3B expression showed a signiﬁcantly
worse outcome than patients with lower DNMT3B expression
(Figure 1b). The 5-year OS and EFS of patients with higher DNMT3B
expression were 16.7%±6.2% (P= 0.001) and 16.7%±6.2%
(P= 0.005) compared to 47.6%± 8.8% and 39.0%±8.6% in patients
with lower DNMT3B expression. The survival of patients with
co-occurring NPM1 and FLT3-ITD mutations is negatively inﬂuenced
by high FLT3-ITD allelic burden.11–13 Higher DNMT3B expression
was observed in both patients with low and those with high FLT3-
ITD allelic burden (Supplementary Table S2). We next analyzed
whether DNMT3B expression had an effect on survival among
these subgroups. Higher DNMT3B expression did not exhibit a
signiﬁcant effect on OS and EFS among patients with low FLT3-ITD
allelic burden (data not shown). However, patients with higher
DNMT3B expression showed an extremely poor OS and EFS (5-year
OS: 0.0%±0.0%, 5-year EFS: 0.0%±0.0%, Po0.001), compared to
patients with lower DNMT3B expression (5-year OS: 38.9%±12.9%,
5-year EFS: 32.0%±12.4%) within the subgroup with high FLT3-ITD
allelic burden (Figure 1c). In multivariate analysis, higher DNMT3B
expression showed an independent prognostic value for OS and
EFS, with a high hazard ratio both in the NPM1+/FLT3-ITD+
subgroup (HR: 4.850, 95% CI: 1.980–11.880) and among those
patients with high FLT3-ITD allelic burden, indicating that the latter
subgroup can be separated into two groups, one with an
intermediate and the other with an extremely poor survival,
based on DNMT3B expression (Table 1).
In conclusion, these data show that higher DNMT3B expression
is a strong independent predictive factor for poor disease
Citation: Blood Cancer Journal (2014) 4, e233; doi:10.1038/bcj.2014.51
© 2014 Macmillan Publishers Limited All rights reserved 2044-5385/14
www.nature.com/bcj
outcome in AML in general, and especially among NPM1+/FLT3-
ITD+ patients with normal karyotype. Drugs that inhibit DNA
methylation are tested for clinical efﬁcacy in AML.1–4 Because
DNMT3B catalyzes DNA methylation, its expression level
may affect the therapeutic sensitivity to these drugs. Thus, it
will be interesting to investigate whether DNMT3B expression
predicts therapy responses to treatments affecting DNA
methylation.
Figure 1. Higher DNMT3B expression correlates with inferior OS and EFS in AML. (a) Kaplan–Meier plots for OS and EFS showed that higher
DNMT3B expression correlated signiﬁcantly with a poor OS and EFS among AML patients (5-year OS: 17.2%± 3.3% vs 43.8%± 2.5% and 5-year
EFS: 13.6%± 3.0% vs 34.4%± 2.4% for patients with higher and lower DNMT3B expression, respectively). (b) Higher DNMT3B expression
predicted a very poor OS and EFS among patients with normal karyotype carrying NPM1 and FLT3-ITD mutations compared to patients with
lower DNMT3B expression (5-year OS: 16.7± 6.2% vs 47.6± 8.8%, P= 0.001 and 5-year EFS: 16.7± 6.2% vs 39.0± 8.6%, P= 0.005 for patients
with higher and lower DNMT3B expression, respectively). (c) Within the group of patients with normal karyotype that carries NPM1 mutations
with high FLT3-ITD allelic burden, higher DNMT3B expression correlated with an extremely poor OS and EFS compared to patients with lower
DNMT3B expression (5-year OS: 0%± 0.0% vs 38.9%± 12.9%, Po0.001 and 5-year EFS: 0%± 0.0% vs 32.0%± 12.4%, Po0.001 for patients with
higher and lower DNMT3B expression, respectively). P values were determined with the log-rank test. In agreement with de Jonge et al.,13 high
FLT3-ITD allelic burden was deﬁned as an allelic FLT3-ITD/FLT3 ratio 41.
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Table 1. Data proving that DNMT3B expression is a prognostic factor in AML, particularly in NPM1+/ FLT3-ITD+ patients with normal karyotype
OS EFS
HR (95% CI) P HR (95% CI) P
AML
Higher DNMT3B exp. 1.768 (1.384–2.260) o0.001 1.706 (1.342–2.168) o0.001
Age460 years 1.523 (1.111–2.087) 0.009 1.339 (0.985–1.821) 0.063
WBC count4100 ×109/l 1.448 (1.098–1.909) 0.009 1.531 (1.173–1.997) 0.002
FLT3-ITD mutations 1.675 (1.287–2.179) o0.001 1.649 (1.274–2.136) o0.001
NPM1 mutations 0.397 (0.291–0.541) o0.001 0.381 (0.280–0.518) o0.001
Favorable karyotype 0.388 (0.266–0.565) o0.001 0.457 (0.323–0.646) o0.001
CEBPA double mutation 0.338 (0.177–0.645) 0.001 0.361 (0.199–0.653) 0.001
DNMT3A mutations 1.631 (1.204–2.210) 0.002 1.531 (1.136–2.063) 0.005
EVI1 overexpression 1.430 (0.999–2.047) 0.051 1.711 (1.208–2.423) 0.002
Transplantation status 0.700 (0.610–0.806) o0.001 0.758 (0.665–0.865) o0.001
Normal karyotype
NPM1+/FLT3-ITD+
Higher DNMT3B expression 3.090 (1.623–5.883) 0.001 2.414 (1.309–4.451) 0.005
Age460 years 2.703 (1.134–6.438) 0.025 1.951 (0.831–4.583 0.125
WBC count4100 ×109/l 2.365 (1.270–4.404) 0.007 1.763 (0.958–3.246) 0.069
High FLT3-ITD AB 3.791 (1.971–7.294) o0.001 3.130 (1.685–5.813) o0.001
NPM1+/FLT3-ITD+ with high FLT3-ITD AB
Higher DNMT3B expression 4.850 (1.980–11.880) 0.001 4.428 (1.824–10.749) 0.001
Age460 years 2.007 (0.660–6.101) 0.219 1.478 (0.489–4.464) 0.489
WBC count4100 ×109/l 1.356 (0.634–2.901) 0.433 0.954 (0.446–2.043) 0.904
Abbreviations: AB, allelic burden; 95% CI, 95% conﬁdence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; WBC, white blood cell.
Multivariate Cox regression model for probability of OS and EFS. Favorable karyotype includes inv(16), t(8;21) and t(15;17). Transplantation status includes no
transplantation, autologous transplantation or allogeneic transplantation. Age and WBC count are dichotomized. DNMT3B expression is dichotomized in
multivariate analysis. P-values (bold) indicate whether differences are signiﬁcant at the level of 0.05.
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